Aurobindo Pharma Limited (AUROPHARMA) - Total Assets
Based on the latest financial reports, Aurobindo Pharma Limited (AUROPHARMA) holds total assets worth Rs585.02 Billion INR (≈ $6.33 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Aurobindo Pharma Limited to assess the company's total reinvestment commitment from operating cash flow.
Aurobindo Pharma Limited - Total Assets Trend (2004–2026)
This chart illustrates how Aurobindo Pharma Limited's total assets have evolved over time, based on quarterly financial data. Explore Aurobindo Pharma Limited (AUROPHARMA) investment intensity to see how much of total assets are deployed in long-term investments.
Aurobindo Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2026)
Aurobindo Pharma Limited's total assets of Rs585.02 Billion consist of 55.9% current assets and 44.1% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 16.9% |
| Accounts Receivable | Rs71.12 Billion | 12.2% |
| Inventory | Rs120.53 Billion | 20.6% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs44.81 Billion | 7.7% |
| Goodwill | Rs8.00 Billion | 1.4% |
Asset Composition Trend (2004–2026)
This chart illustrates how Aurobindo Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Aurobindo Pharma Limited (AUROPHARMA) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aurobindo Pharma Limited's current assets represent 55.9% of total assets in 2026, an increase from 51.4% in 2004.
- Cash Position: Cash and equivalents constituted 16.9% of total assets in 2026, up from 3.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 1.0% in 2004.
- Asset Diversification: The largest asset category is inventory at 20.6% of total assets.
Aurobindo Pharma Limited Competitors by Total Assets
Key competitors of Aurobindo Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Bausch Health Companies Inc
TO:BHC
|
Canada | CA$24.50 Billion |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
China | CN¥4.80 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Hainan Haiyao Co Ltd
SHE:000566
|
China | CN¥5.79 Billion |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
China | CN¥4.51 Billion |
Aurobindo Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.81 | 1.85 | 1.86 |
| Quick Ratio | 1.15 | 1.13 | 1.01 |
| Cash Ratio | 0.00 | 0.56 | 0.00 |
| Working Capital | Rs146.70 Billion | Rs124.80 Billion | Rs91.58 Billion |
Aurobindo Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Aurobindo Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.20 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 17.5% |
| Total Assets | Rs585.02 Billion |
| Market Capitalization | $9.32 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Aurobindo Pharma Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aurobindo Pharma Limited's assets grew by 17.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aurobindo Pharma Limited (2004–2026)
The table below shows the annual total assets of Aurobindo Pharma Limited from 2004 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs585.02 Billion ≈ $6.33 Billion |
+17.51% |
| 2025-03-31 | Rs497.85 Billion ≈ $5.38 Billion |
+10.46% |
| 2024-03-31 | Rs450.72 Billion ≈ $4.87 Billion |
+12.99% |
| 2023-03-31 | Rs398.90 Billion ≈ $4.31 Billion |
+17.59% |
| 2022-03-31 | Rs339.22 Billion ≈ $3.67 Billion |
+0.20% |
| 2021-03-31 | Rs338.54 Billion ≈ $3.66 Billion |
+17.03% |
| 2020-03-31 | Rs289.28 Billion ≈ $3.13 Billion |
+9.35% |
| 2019-03-31 | Rs264.54 Billion ≈ $2.86 Billion |
+25.37% |
| 2018-03-31 | Rs211.01 Billion ≈ $2.28 Billion |
+29.86% |
| 2017-03-31 | Rs162.49 Billion ≈ $1.76 Billion |
+2.07% |
| 2016-03-31 | Rs159.20 Billion ≈ $1.72 Billion |
+23.27% |
| 2015-03-31 | Rs129.14 Billion ≈ $1.40 Billion |
+36.09% |
| 2014-03-31 | Rs94.90 Billion ≈ $1.03 Billion |
+30.39% |
| 2013-03-31 | Rs72.78 Billion ≈ $787.07 Million |
+16.68% |
| 2012-03-31 | Rs62.38 Billion ≈ $674.58 Million |
+6.22% |
| 2011-03-31 | Rs58.72 Billion ≈ $635.06 Million |
+22.56% |
| 2010-03-31 | Rs47.91 Billion ≈ $518.16 Million |
+13.36% |
| 2009-03-31 | Rs42.26 Billion ≈ $457.08 Million |
+16.29% |
| 2008-03-31 | Rs36.34 Billion ≈ $393.06 Million |
+3.65% |
| 2007-03-31 | Rs35.06 Billion ≈ $379.21 Million |
+30.38% |
| 2006-03-31 | Rs26.89 Billion ≈ $290.85 Million |
+26.28% |
| 2005-03-31 | Rs21.30 Billion ≈ $230.33 Million |
+14.14% |
| 2004-03-31 | Rs18.66 Billion ≈ $201.79 Million |
-- |
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system,… Read more